Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

BACKGROUND: The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, might foster innate and adaptive immune response and thus improve immune-mediated control of residual cancer disease. The IMPULSE phase II study evaluated the efficacy and safety of lefitolimod as mainte...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, M, Ponce-Aix, S, Navarro, A, Riera-Knorrenschild, J, Schmidt, M, Wiegert, E, Kapp, K, Wittig, B, Mauri, C, Dómine Gómez, M, Kollmeier, J, Sadjadian, P, Fröhling, K -P, Huber, R M, Wolf, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225892/
https://www.ncbi.nlm.nih.gov/pubmed/30137193
http://dx.doi.org/10.1093/annonc/mdy326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225892/
https://www.ncbi.nlm.nih.gov/pubmed/30137193
http://dx.doi.org/10.1093/annonc/mdy326

Ejemplares similares